Potential of immunomodulatory host defense peptides as novel anti-infectives

Trends in Biotechnology

Volumn 27, Issue 10, 2009, Pages 582-590

  Easton, Donna M ^a   Nijnik, Anastasia ^a   Mayer, Matthew L ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFECTIVES; ANTIMICROBIAL ACTION; ANTIMICROBIAL DRUG; CLINICAL USE; CURRENT LIMITATION; HOST DEFENSE; HOST IMMUNE RESPONSE; INFECTIOUS AGENTS; INFECTIOUS DISEASE; INNATE DEFENSE; INNATE IMMUNITY; NEW STRATEGY; TISSUE DAMAGE;

AMINES;

PEPTIDES;

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLOSPORIN; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DIAPEP277; EA 230; GLUCOCORTICOID; GLUTOXIM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HB 1345; HLF 1-11; IB 367; IMIQUIMOD; IMX 942; INNATE DEFENSE REGULATOR; INNATE DEFENSE REGULATOR 1; INTERFERON; MX 226; NOV 002; OMIGANAN; OPEBACAN; PAC 113; PEXIGANAN ACETATE; PLACEBO; PMX 30063; POLYPEPTIDE ANTIBIOTIC AGENT; RAPAMYCIN; TACROLIMUS; TGN 1412; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; XOMA 629;

ACNE; ACNE VULGARIS; ADOPTIVE TRANSFER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BACTEREMIA; BASAL CELL CARCINOMA; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOKINE STORM; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTOXEMIA; ENTERITIS; FEBRILE NEUTROPENIA; GRAFT REJECTION; HEPATITIS B; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMPETIGO; INFECTION; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; LUNG TUBERCULOSIS; METABOLIC DISORDER; MILIARY TUBERCULOSIS; MYCOSIS; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; ROSACEA; SEPSIS; SIGNAL TRANSDUCTION; STOMATITIS; SYSTEMS BIOLOGY; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS INFECTION; WOUND HEALING;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC FACTORS;

EID: 69949086979     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2009.07.004     Document Type: Review

References (80)

1. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat. Med. 10 (2004) 1177-1185
2. WHO (2008) World Health Statistics 2008, World Health Organisation Press
3. Weiss R.A., and McMichael A.J. Social and environmental risk factors in the emergence of infectious diseases. Nat. Med. 10 (2004) S70-76
4. Spellberg B., et al. The epidemic of antibiotic resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46 (2008) 155-164
5. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 9 (2003) 269-277
6. Hamill P., et al. Novel anti-infectives: is host defence the answer?. Curr. Opin. Biotechnol. 19 (2008) 628-636
7. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov. Today 12 (2007) 80-87
8. Kanzler H., et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13 (2007) 552-559
9. Pashine A., et al. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11 (2005) S63-68
10. Harper D.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
11. Viola A., and Luster A.D. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 171-197
12. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5 (2006) 549-563
13. Figdor C.G., et al. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10 (2004) 475-480
14. Rosenberg S.A., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8 (2008) 299-308
15. Dinarello C.A. Anti-cytokine therapeutics and infections. Vaccine 21 Suppl. 2 (2003) S24-34
16. Askling J., and Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20 (2008) 334-339
17. Ponce R. Adverse consequences of immunostimulation. J. Immunotoxicol. 5 (2008) 33-41
18. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006) 1018-1028
19. O'Callaghan A., and Redmond H.P. Treatment of sepsis: current status of clinical immunotherapy. Surgeon 4 (2006) 355-361
20. Schadt E.E., et al. A network view of disease and compound screening. Nat. Rev. Drug Discov. 8 (2009) 286-295
21. Brown K.L., et al. Complexities of targeting innate immunity to treat infection. Trends Immunol. 28 (2007) 260-266
22. Hancock R.E.W., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24 (2006) 1551-1557
23. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75 (2004) 39-48
24. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3 (2003) 710-720
25. Kavanagh K., and Dowd S. Histatins: antimicrobial peptides with therapeutic potential. J. Pharm. Pharmacol. 56 (2004) 285-289
26. Powers J.P., and Hancock R.E.W. The relationship between peptide structure and antibacterial activity. Peptides 24 (2003) 1681-1691
27. Bowdish D.M., et al. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77 (2005) 451-459
28. Bowdish D.M., et al. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49 (2005) 1727-1732
29. Scott M.G., et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25 (2007) 465-472
30. Cherkasov A., et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem. Biol. 4 (2009) 65-74
31. Fjell C.D., et al. Identification of novel antibacterial peptides by chemoinformatics and machine learning. J. Med. Chem. 52 (2009) 2006-2015
32. Mookherjee N., et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176 (2006) 2455-2464
33. Dankesreiter S., et al. Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J. Immunol. 164 (2000) 4804-4811
34. Nagaoka I., et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin. Diagn. Lab. Immunol. 9 (2002) 972-982
35. Braff M.H., et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174 (2005) 4271-4278
36. Garlapati S., et al. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet. Immunol. Immunopathol. 128 (2009) 184-191
37. Kovacs-Nolan J., et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 27 (2009) 2055-2064
38. Kindrachuk J., et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27 (2009) 4662-4671
39. Bowdish D.M., et al. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6 (2005) 35-51
40. Lau, Y.E. et al. (2005) Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun. 73, 583-591 41
41. Mookherjee, N. et al., Intracellular receptor for human host defence peptide LL-37 in monocytes. J. Immunol. (in press) DOI:10.4049/jimmunol.0802586, Epub ahead of print PMFD 19605696
42. Travis S., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. 11 (2005) 713-719
43. Holtmann M.M. RDP-58 (SangStat Medical). IDrugs 6 (2003) 1188-1194
44. Xavier R.J., and Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007) 427-434
45. Giacometti A., et al. Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. Peptides 24 (2003) 1747-1752
46. Sokolova, G.B. et al. (2002) [Glutoxim in the complex treatment of tuberculosis]. Antibiot. Khimioter. 47, 20-23 (English translation available at http://www.glutoxim.ru/eng/index.php?id=9&issueId=2)
47. Fimiani V., et al. Immunomodulatory effect of glutoxim on some activities of isolated human neutrophils and in whole blood. Immunopharmacol. Immunotoxicol. 24 (2002) 627-638
48. Fischer P.M. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr. Protein Pept. Sci. 4 (2003) 339-356
49. Kraus D., and Peschel A. Staphylococcus aureus evasion of innate antimicrobial defense. Future Microbiol. 3 (2008) 437-451
50. Andra J., et al. Mechanisms of endotoxin neutralization by synthetic cationic compounds. J. Endotoxin Res. 12 (2006) 261-277
51. Lynn D.J., et al. InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol. Syst. Biol. 4 (2008) 218
52. Mookherjee N., et al. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol. Biosyst. 5 (2009) 483-496
53. Nguyen T.X., et al. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 24 (2003) 1647-1654
54. Carretero M., et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 128 (2008) 223-236
55. Steinstraesser L., et al. Host defense peptides in wound healing. Mol. Med. 14 (2008) 528-537
56. Weber G., et al. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res. 11 (2009) R6
57. Coffelt S.B., et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3806-3811
58. Lingnau K., et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20 (2002) 3498-3508
59. Schellack C., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 (2006) 5461-5472
60. Stevceva L., and Ferrari M.G. Mucosal adjuvants. Curr. Pharm. Des. 11 (2005) 801-811
61. Soehnlein O., et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 112 (2008) 1461-1471
62. Elssner A., et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release. J. Immunol. 172 (2004) 4987-4994
63. Barlow P.G., et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J. Leukoc. Biol. 80 (2006) 509-520
64. Zheng Y., et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human α-defensins from neutrophils. Br. J. Dermatol. 157 (2007) 1124-1131
65. Di Nardo A., et al. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170 (2003) 2274-2278
66. 2 production from mast cells. Eur. J. Immunol. 31 (2001) 1066-1075
67. Davidson D.J., et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172 (2004) 1146-1156
68. Kandler K., et al. The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int. Immunol. 18 (2006) 1729-1736
69. Biragyn A., et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298 (2002) 1025-1029
70. Lande R., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007) 564-569
71. Yamasaki K., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 13 (2007) 975-980
72. Tokumaru S., et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol. 175 (2005) 4662-4668
73. Tjabringa G.S., et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171 (2003) 6690-6696
74. Pistolic J., et al. Host defence peptide LL-37 induces IL-6 expression in human bronchial epithelial cells by activation of the NF-κB pathway. J. Innate Immun. 1 (2008) 254-267
75. Otte J.M., et al. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul. Pept. 156 (2009) 104-117
76. Wehkamp J., et al. Defensins and cathelicidins in gastrointestinal infections. Curr. Opin. Gastroenterol. 23 (2007) 32-38
77. Koczulla R., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111 (2003) 1665-1672
78. von Haussen J., et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 59 (2008) 12-23
79. Chuang C.M., et al. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther. 20 (2009) 303-313
80. van den Berg H.R., et al. Synthetic oligopeptides related to the β-subunit of human chorionic gonadotropin attenuate inflammation and liver damage after (trauma) hemorrhagic shock and resuscitation. Shock 31 (2009) 285-291